Jabil Inc vs uniQure N.V. Ordinary Shares — how do they compare? Jabil Inc trades at $288 (market cap $33.31B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Jabil Inc is far larger — about 22.5× uniQure N.V. Ordinary Shares's market cap, and Jabil Inc pays a 0.1% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 24 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| JBL | QURE | |
|---|---|---|
Market Cap | $33.31B | $1.48B |
Volume | 1,264,382 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $385.50 | $70.59 |
52-Week Low | $192.49 | $9.03 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $35.59B | $728.62M |
Dividend Yield | 0.1% | — |
Signals from Pluang's Aura AI — not financial advice
JBL trades at $317.86, up 1.87% with strong technical momentum and bullish moving averages. The company delivered three consecutive earnings beats, with Q2 2026 EPS of $4.40 beating expectations of $4.07. Revenue growth is accelerating, with fiscal 2027 guidance projecting 24% growth driven by AI infrastructure demand. Analyst consensus remains strongly bullish with a $434.75 price target representing 37% upside potential.
The outlook remains positive with AI-driven growth catalysts and strong institutional support, though risks include execution challenges in scaling operations and market volatility despite strong fundamentals. Current valuation at 32.6 P/E appears reasonable given the growth trajectory, while the 74.11% ROE demonstrates exceptional capital efficiency.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →